# A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

> **NCT03396211** · PHASE1 · COMPLETED · sponsor: **Elevar Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03396211
- **Lead sponsor:** Elevar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-22
- **Primary completion:** 2020-10-28
- **Final completion:** 2022-03-16
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03396211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03396211, "A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03396211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*